Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biotechnology company that develops a class of genetic medicines called Endosomal Escape Vehicles (EEVs). The EEV platform is meant to deliver intracellular therapeutics, such as oligonucleotides, proteins and other biologics, into cells. The company's mission is to treat serious diseases, including neuromuscular conditions such as Duchenne muscular dystrophy and myotonic dystrophy type 1. Its pipeline also includes programs in ocular and other diseases.